Literature DB >> 16173238

Development of a functional disability measurement tool to assess early arthritis: the Recent-Onset Arthritis Disability (ROAD) questionnaire.

F Salaffi1, L Bazzichi, A Stancati, R Neri, M Cazzato, A Consensi, W Grassi, S Bombardieri.   

Abstract

OBJECTIVE: To develop a self-administered questionnaire, the ROAD (Recent-Onset Arthritis Disability), to probe physical disability in Italian patients with early arthritis (EA) of less than one year's duration.
METHODS: The development of the ROAD follows a series of major steps: (1) identification of a specific patient population, (2) item pool development, (3) item reduction, (4) internal consistency, (5) pre-testing of the prototype instrument, and (6) a validation study which results in determination, reliability, validity and responsiveness. In this study we have verified the first five steps. Pre-defined areas of disability were culled from eight existing Italian version arthritis-specific questionnaires, and three generic global health measurement tools. Semi-structured interviews helped to derive a 76-item pool from an initial group of 122 items. This questionnaire was administered to 78 EA patients.
RESULTS: For scale generation, a combination of frequency importance product (FIP = frequency x mean relevance score) and factor analysis was applied. The top 20 items based on the FIP were then subjected to further analysis. Each question was correlated with every other question. This allowed us to eliminate 8 questions that were therefore highly correlated and were measuring the same concept. The final instrument has 12 items, representing a combination of symptoms that are common, frequently recurring and of general importance to EA patients. Factor analysis provides a 3-factor health status model explaining 70.1% of the variance. The upper extremity function (5 items) is loaded on the first factor, which explains 45.4% of the total measured variance. The lower extremity function (4 items) formed the second factor (14.2% of the total variance). The third factor was determined by activities of daily living/work (3 items) and explain 10.5% of the total variance. The score of the different subscales can be presented graphically as a ROAD profile.
CONCLUSION: Using a traditional development strategy, we have constructed a self-administered instrument for measuring physical functioning in patients with EA. The next stage includes reliability, validity and responsiveness testing of the 12-item questionnaire.

Entities:  

Mesh:

Year:  2005        PMID: 16173238

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

1.  The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia.

Authors:  Fausto Salaffi; Marco Di Carlo; Marina Carotti; Piercarlo Sarzi-Puttini
Journal:  Rheumatol Int       Date:  2018-06-28       Impact factor: 2.631

2.  The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis.

Authors:  Fausto Salaffi; Maria Chiara Gerardi; Fabiola Atzeni; Alberto Batticciotto; Rossella Talotta; Antonella Draghessi; Marco Di Carlo; Piercarlo Sarzi-Puttini
Journal:  Rheumatol Int       Date:  2017-09-05       Impact factor: 2.631

3.  The value of ultrasound and magnetic resonance imaging scoring systems in explaining handgrip strength and functional impairment in rheumatoid arthritis patients: a pilot study.

Authors:  Fausto Salaffi; Marina Carotti; Marco Di Carlo; Luca Ceccarelli; Sonia Farah; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2022-05-14       Impact factor: 6.313

4.  Classical test theory and Rasch analysis validation of the Recent-Onset Arthritis Disability questionnaire in rheumatoid arthritis patients.

Authors:  Fausto Salaffi; Franco Franchignoni; Andrea Giordano; Alessandro Ciapetti; Stefania Gasparini; Marcella Ottonello
Journal:  Clin Rheumatol       Date:  2012-10-13       Impact factor: 2.980

Review 5.  [Early rheumatoid arthritis--rapid help is double help].

Authors:  M Aringer; N Leuchten; K P Machold
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

6.  Relative importance of the functional abilities comprising Health Assessment Questionnaire Disability Index among rheumatoid arthritis patients.

Authors:  Risto Tuominen; Timo Möttönen; Carita Suominen; Tero Vahlberg; Sini Tuominen
Journal:  Rheumatol Int       Date:  2009-10-14       Impact factor: 2.631

Review 7.  Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: a systematic review of the literature.

Authors:  Martijn A H Oude Voshaar; Peter M ten Klooster; Erik Taal; Mart A F J van de Laar
Journal:  Health Qual Life Outcomes       Date:  2011-11-07       Impact factor: 3.186

8.  Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care.

Authors:  Fausto Salaffi; Marina Carotti; Marwin Gutierrez; Marco Di Carlo; Rossella De Angelis
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

9.  Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference.

Authors:  Mona Dür; Michaela Coenen; Michaela Alexandra Stoffer; Veronika Fialka-Moser; Alexandra Kautzky-Willer; Ingvild Kjeken; Răzvan Gabriel Drăgoi; Malin Mattsson; Carina Boström; Josef Smolen; Tanja Alexandra Stamm
Journal:  Health Qual Life Outcomes       Date:  2015-02-25       Impact factor: 3.186

10.  Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect.

Authors:  Fausto Salaffi; Piercarlo Sarzi-Puttini; Rita Girolimetti; Stefania Gasparini; Fabiola Atzeni; Walter Grassi
Journal:  Arthritis Res Ther       Date:  2009-08-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.